Close X
Attorney Spotlight

How does Jordana Nelson's prior experience as a general counsel inform her work with firm clients? Read more>

Search

Close X

Experience

Search our Experience

Experience Spotlight

The M&A Advisor Winner 2017The M&A Advisor announced the winners of the 16th Annual M&A Advisor Awards on Monday, November 13 at the 2017 M&A Advisor Awards. Bass, Berry & Sims was named a winner in the two categories related to the following deals:

M&A Deal of the Year (from $1B-$5B) – Acquisition of CLARCOR Inc. by Parker Hannifin Corporation

Corporate/Strategic Deal of the Year (over $1B) – Acquisition of BNC Bancorp by Pinnacle Financial Partners

Close X

Thought Leadership

Enter your search terms in the relevant box(es) below to search for specific Thought Leadership.
To see a recent listing of Thought Leadership, click the blue Search button below.

Thought Leadership Spotlight

Regulation A+

It seems that lately there has been a noticeable uptick in Regulation A+ activity, including several recent Reg A+ securities offerings where the stock now successfully trades on national exchanges. In light of this activity, we have published a set of FAQs about Regulation A+ securities offerings to help companies better understand this "mini-IPO" offering process, as well as pros and cons compared to a traditional underwritten IPO.

Read now

Terry Clark Provides Insight on Impact of Federal Circuit's Ruling on Drugmakers' Use of Third-Party Manufacturing Vendors

Law360

Media Mentions

July 13, 2016

Bass, Berry & Sims attorney Terry Clark provided comments for an article in Law360 outlining the Federal Circuit's en banc decision in Medicines Co. as to under what circumstances would use of a third-party vendor trigger an invalidating on-sale bar in patent cases. The decision provides, among other things, that contracting with a third-party vendor to manufacture a product covered by process patent claims does not per se constitute an "on-sale" bar. As Terry points out in the article, the "court reached 'a very practical decision' reflecting a trend in the pharmaceutical industry (and elsewhere) to outsource drug manufacturing to third parties. 'They seem to have realized that it would probably be unfair to penalize those companies that don't have the ability to manufacture in-house.'" In light of this decision, drugmakers should carefully review and formalize their agreements with third-party vendors.

The full article, "Fed. Circ. Ruling Blunts On-Sale Bar's Threat To Patents," was published by Law360 on July 11, 2016, and is available online.


Related Professionals

Related Services

Notice

Visiting, or interacting with, this website does not constitute an attorney-client relationship. Although we are always interested in hearing from visitors to our website, we cannot accept representation on a new matter from either existing clients or new clients until we know that we do not have a conflict of interest that would prevent us from doing so. Therefore, please do not send us any information about any new matter that may involve a potential legal representation until we have confirmed that a conflict of interest does not exist and we have expressly agreed in writing to the representation. Until there is such an agreement, we will not be deemed to have given you any advice, any information you send may not be deemed privileged and confidential, and we may be able to represent adverse parties.